good point, checking back on the SPP focus is oral formulation for FTO inhibitor and non-cancer indications.
checking further into Colorectal cancer. Third highest cancer diagnosis. 5-FU is the backbone treatment but approx 25% results in liver or lung metastasis. From what I could find out 90% of metastasis are resistant to treatment. Overall poor prognosis if resistant.
This is where FTO inhibition and per Dr Chens paper Zantrene (CS1) can overcome resistance.
Unfortunately can pursue all targets right now but this seems promising for a future opportunity.
Ann: Zantrene data published in Cancer Research Journal, page-39
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.52 |
Change
-0.030(1.94%) |
Mkt cap ! $258.9M | |||
| Open | High | Low | Value | Volume |
| $1.57 | $1.57 | $1.50 | $75.34K | 49.79K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 300 | $1.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.52 | 49256 | 1 |
View Market Depth
| Last trade - 16.10pm 19/08/2024 (20 minute delay) ? |
| RAC (ASX) Chart |